Hadlima

July 24, 2022

Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) announced the FDA approval of the citrate-free, high-concentration (100 mg/mL) formulation of HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA^® (adalimumab). HADLIMA will be available in pre-filled syringes and autoinjector options. The autoinjector was specifically designed with the patient in mind.

Hadlima is the fourth FDA approved biosimilar to adlimumbad
It is a tumor necrosis factor (TNF) blocker for Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn’s Disease, and Ulcerative Colitis.
Planned launch in the S. is in 2023

Related News

About 6% of U.S. Adults Have ADHD, Drug Shortages Are Affecting Treatment

October 10, 2024

OTULFI™

September 30, 2024

FLYRCADO

September 27, 2024

Benefit Advisors & Employees - Want to know more?

Members: Please call the number on the back of your ID card or e-mail member.services@benecardpbf.com Clients: Contact your Client Relations Manager

By submitting this form, you are consenting to receive marketing emails from: Benecard Services, LLC. (Lawrenceville, NJ 08648), https://www.benecard.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact.